MAPT and Alzheimer disease: Studies of AD pharmaceutical intervention are mainly focused on cholinesterase inhibition, anti-NMDA, Aβ-directed therapeutics, tau-directed therapeutics, ApoE-directed therapeutics and combination therapies [1].